UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε...

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• T-cell lymphomas (TCLs) are aggressive hematologic malignancies often resistant to conventional therapies.
• UMG1 is a unique CD43 epitope expressed on T-cell malignancies but largely absent in normal tissues.
• Previous studies demonstrated UMG1/CD3ε-BTCE efficacy against T-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

Purpose of the Study:

• To investigate the in vitro efficacy of the UMG1/CD3ε-BTCE against various types of T-cell lymphomas.
• To assess UMG1 expression levels in TCL patient samples and cell lines.
• To evaluate the potential of UMG1/CD3ε-BTCE as a precision immunotherapy for TCLs.

Main Methods:

• Immunohistochemistry (IHC) analysis of Tissue Micro Arrays (TMAs) for UMG1 expression in TCL samples.
• Flow cytometry to detect UMG1 expression on TCL cell lines.
• In vitro assessment of UMG1/CD3ε-BTCE-mediated redirected cytotoxicity against UMG1-expressing TCL cells.
• Evaluation of the synergistic effect of UMG1/CD3ε-BTCE with HDAC inhibitor SAHA.

Main Results:

• High UMG1 expression was found in 62.3% of TCL samples, including PTCL-NOS and ALK-negative ALCL.
• All T-cell prolymphocytic leukemia (T-PLL) specimens (27/27) and most TCL cell lines expressed UMG1.
• UMG1/CD3ε-BTCE induced robust, dose-dependent T-cell-mediated cytotoxicity and inflammatory cytokine release against UMG1-expressing TCL cells.
• The efficacy of UMG1/CD3ε-BTCE was enhanced by co-treatment with SAHA.

Conclusions:

• UMG1/CD3ε-BTCE demonstrates selective and potent anti-tumor activity against a significant subset of T-cell lymphomas.
• UMG1 expression is a viable biomarker for identifying TCL patients who may benefit from UMG1/CD3ε-BTCE therapy.
• These findings support the development of UMG1/CD3ε-BTCE as a precision immunotherapy for UMG1-expressing aggressive hematologic malignancies.